Abstract: Methods and compositions for treating bedwetting are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents.

Abstract: Methods and compositions for treating bedwetting are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents.

Abstract: Compositions for reducing the frequency of urination and methods of manufacturing the compositions are disclosed. The compositions comprises a first component having an immediate-release subcomponent and an extended-release subcomponent, wherein the first component is formulated to release the subcomponents immediately after administration; and a second component comprising an immediate-release subcomponent and an extended-release subcomponent, wherein the second component is formulated for a delayed-release of the subcomponents.

Abstract: A method for manufacturing a pharmaceutical composition for reducing the frequency of urination is disclosed. The pharmaceutical composition comprises (1) an analgesic agent and (2) an ?-blocker, a 5?-reductase inhibitor or both.

Abstract: A method for monitoring and modifying behavior to reduce negative effects, including the steps of receiving, via a user interface of an application executing on one or more computer processors, a negative information report about one or more discriminatory acts or offensive behaviors known or alleged to have been committed by an individual or entity; assigning, via the one or more computer processors, a negative information point value for any of a plurality of discriminatory acts or offensive behaviors and a discriminatory/offensive behaviors point matrix stored on a memory device accessible by the one or more computer processors, the discriminatory/offensive behaviors point matrix being generated and continually updated by a machine learning module; storing the negative information report on a negative information database; notifying the individual or entity about the negative information report; and providing a website for reporting negative information reports under certain specified conditions.

Abstract: Compositions and methods for reducing body weight in a subject are disclosed. In one aspect, a method for reducing body weight in a subject comprises: administering to a subject in need thereof a pharmaceutical composition comprising acetaminophen in an amount sufficient for reducing body weight, wherein the acetaminophen is administered orally at a daily dose of 5 mg to 2000 mg, and wherein the composition is formulated in a controlled release formulation. The acetaminophen may be administered alone or in combination with an anti-obesity drug, an appetite suppressant, a diacylglycerol acyltransferase (DGAT) inhibitor, a lipase inhibitor, a onsteroidal anti-inflammatory drugs (NSAIDs), a Type II diabetes agents, anti-insomnia agents or a combination thereof.

Abstract: Compositions for reducing the frequency of urination and methods of manufacture of the compositions are disclosed. One method of manufacture include the steps of forming a first mixture comprising a first active ingredient comprising one or more analgesic, coating the first mixture with a first delayed-release coating to form a first component, forming a second mixture comprising a second active ingredient comprising one or more analgesic agents, coating the second mixture with a second delayed-release coating to form a second component, and combining the first component with the second component to form a third mixture.

Abstract: A method for processing information for mentoring service to at-risk people is described. Also describes is a system for implementing the method and a tangible computer readable medium for storing instructions that, when executed by computer processor, causes the computer processor to process information according to the method of the present application.

Abstract: Compositions for reducing the frequency of urination and methods of manufacture of the compositions are disclosed. One method of manufacture include the steps of forming a first mixture comprising a first active ingredient comprising one or more analgesic, coating the first mixture with a first delayed-release coating to form a first component, forming a second mixture comprising a second active ingredient comprising one or more analgesic agents, coating the second mixture with a second delayed-release coating to form a second component, and combining the first component with the second component to form a third mixture.

Abstract: A method for providing incentive to mentors of at-risk mentees is described. The method comprises the steps of determining an at-risk mentee's behavior and progress in a period of time, determining the mentee's income and income tax payments during the same period of time, and calculating a financial incentive to the mentee's mentor, wherein the amount of the financial incentive is calculated based on the mentee's behavior and/or income tax payment during the period of time.

Abstract: A method for processing information for mentoring service to at-risk people is described. Also describes is a system for implementing the method and a tangible computer readable medium for storing instructions that, when executed by computer processor, causes the computer processor to process information according to the method of the present application.

Abstract: Pharmaceutical compositions for reducing frequency of urination are disclosed. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier. Also disclosed are methods of making and using the pharmaceutical compositions.

Abstract: Compositions for reducing the frequency of urination and methods of manufacturing the compositions are disclosed. The compositions comprises a first component having an immediate-release subcomponent and an extended-release subcomponent, wherein the first component is formulated to release the subcomponents immediately after administration; and a second component comprising an immediate-release subcomponent and an extended-release subcomponent, wherein the second component is formulated for a delayed-release of the subcomponents.

Abstract: Methods and compositions for reducing bladder spasms are disclosed. The methods comprise administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of acetaminophen and an effective amount of at least one non-steroidal anti-inflammatory agent (NSAID). In another embodiment, a method for reducing bladder spasms comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of at least one prostaglandin (PG) pathway inhibitor, wherein the at least one PG pathway inhibitor is not acetaminophen or an NSAID.

Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release.

Abstract: Methods and compositions for treating bedwetting are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents.

Abstract: A method for providing incentive to mentors of at-risk mentees is described. The method includes the steps of determining an at-risk mentee's prospects in the absence of mentoring, and then tracking behavior and progress in a period of time, determining the mentee's achievement of important milestones, avoidance of costs to society, and/or income and income tax payments during the same period of time, and calculating a financial incentive to the mentee's mentor, wherein the amount of the financial incentive is calculated based on the mentee's behavior, achievement of important milestones, avoidance of costs to society, and/or income tax payments during the period of time.

Abstract: A method for providing incentive to mentors of at-risk mentees is described. The method includes the steps of determining an at-risk mentee's prospects in the absence of mentoring, and then tracking behavior and progress in a period of time, determining the mentee's achievement of important milestones, avoidance of costs to society, and/or income and income tax payments during the same period of time, and calculating a financial incentive to the mentee's mentor, wherein the amount of the financial incentive is calculated based on the mentee's behavior, achievement of important milestones, avoidance of costs to society, and/or income tax payments during the period of time.

Abstract: Pharmaceutical compositions for reducing frequency of urination are disclosed. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier. Also disclosed are methods of making and using the pharmaceutical compositions.

Abstract: Methods and compositions for reducing frequency of urination are disclosed. The methods comprise administering to a subject having a condition that resulting in undesired frequency of urination an effective amount of a pharmaceutical composition comprising one or more prostaglandin pathway inhibitors. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier.